000			01552cam a2200217 4500
001			9780323755979
008			220107t2020 xxu||||| |||| 00| 0 eng d
020			_a9780323755979
020			_a9780323661812
041			_aeng
100			_aLee, Daniel W.
245		0	_aChimeric antigen receptor T-cell therapies for cancer: a practical guide
260			_aAmsterdam : _bElsevier, _c2020
300			_a1 online resource (xi, 222 pages):illustrations(chiefly color)
505			_aIntroduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome -- Special considerations for ICU management of patients receiving CAR therapy -- Neurotoxicities after CAR-T cell immunotherapy -- Hematologic and non-CRS toxicities -- Response assessment and post-CAR-T cell therapy management -- Relapse management and role for consolidative hematopoietic stem cell transplantation following CAR-T cell therapy -- Promising chimeric antigen receptors for non-B cell hematological malignancies, pediatric solid tumors, and carcinomas -- CAR T cell therapy for CNS malignancies -- CAR 2.0: the next generation of synthetic receptor-based cellular therapy for cancer.
690			_aT cells
690			_aTumor antigens.
700			_aShah, Nirali
856			_uhttps://go.openathens.net/redirector/nhs?url=https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20170040661
999			_c57623 _d57623